Management of alcohol withdrawal syndrome (AWS)
DOI:
https://doi.org/10.12775/QS.2024.16.52923Keywords
alcohol withdrawal syndrome, AWS, AWS management, AWS treatmentAbstract
Alcohol withdrawal syndrome (AWS) is a complex set of symptoms that occur in alcohol-dependent individuals after sudden withdrawal or a significant reduction in alcohol consumption. AWS symptoms occur in about 50% of alcohol abusers. These symptoms may include restlessness, tremor, nausea, nervousness, tachycardia, elevated blood pressure, hyperhidrosis, insomnia, hyperactivity, and hallucinations. In some cases, seizures may occur and delirium tremens may develop, which is life-threatening and an absolute indication for hospitalization of the patient. Effective treatment of AWS is the key to prevent complications and to reduce the risk of death. Treatment of alcohol withdrawal syndrome requires a complex approach that combines properly performed diagnosis, careful monitoring of the patient's condition, pharmacotherapy, equalization of electrolyte disorders, adequate hydration of the patient, supplementation of thiamine deficiencies and, in the case of symptoms of alcoholic delirium, intensive medical care. Pharmacological treatment plays a key role, with the first line of treatment being benzodiazepines, which reduce the risk of epileptic seizures and delirium tremens, and reduce mortality in the course of AWS. Individualized therapy adjustment and patient monitoring are crucial to ensure effective and safe treatment.
References
Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014 May;28(5):401-10. doi: 10.1007/s40263-014-0163-5.
Hall W, Zador D. The alcohol withdrawal syndrome. Lancet. 1997 Jun 28;349(9069):1897-900. doi: 10.1016/S0140-6736(97)04572-8.
Rogawski MA. Update on the neurobiology of alcohol withdrawal seizures. Epilepsy Curr. 2005 Nov-Dec;5(6):225-30. doi: 10.1111/j.1535-7511.2005.00071.x.
Kumar S, Kralic JE, O'Buckley TK, Grobin AC, Morrow AL. Chronic ethanol consumption enhances internalization of alpha1 subunit-containing GABAA receptors in cerebral cortex. J Neurochem. 2003 Aug;86(3):700-8. doi: 10.1046/j.1471-4159.2003.01894.x.
Peng SY, Shi Z, Zhou DS, Wang XY, Li XX, Liu XL, et al. Reduced motor cortex GABABR function following chronic alcohol exposure. Mol Psychiatry. 2021 Feb;26(2):383-395. doi: 10.1038/s41380-020-01009-6.
N'Gouemo P, Caspary DM, Faingold CL. Decreased GABA effectiveness in the inferior colliculus neurons during ethanol withdrawal in rats susceptible to audiogenic seizures. Brain Res. 1996 Jun 17;724(2):200-4. doi: 10.1016/0006-8993(96)00304-6.
Faingold C, Li Y, Evans MS. Decreased GABA and increased glutamate receptor-mediated activity on inferior colliculus neurons in vitro are associated with susceptibility to ethanol withdrawal seizures. Brain Res. 2000 Jun 23;868(2):287-95. doi: 10.1016/s0006-8993(00)02342-8.
Kalluri HS, Mehta AK, Ticku MK. Up-regulation of NMDA receptor subunits in rat brain following chronic ethanol treatment. Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):221-4. doi: 10.1016/s0169-328x(98)00112-0.
Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol. 1990 Feb 13;176(3):289-96. doi: 10.1016/0014-2999(90)90022-x.
Behnke RH. Recognition and management of alcohol withdrawal syndrome. Hosp Pract. 1976 Nov;11(11):79-84. doi: 10.1080/21548331.1976.11707031.
Carlson RW, Kumar NN, Wong-Mckinstry E, Ayyagari S, Puri N, Jackson FK, et al. Alcohol withdrawal syndrome. Crit Care Clin. 2012 Oct;28(4):549-85. doi: 10.1016/j.ccc.2012.07.004.
Schmidt KJ, Doshi MR, Holzhausen JM, Natavio A, Cadiz M, Winegardner JE. Treatment of Severe Alcohol Withdrawal. Ann Pharmacother. 2016 May;50(5):389-401. doi: 10.1177/1060028016629161.
Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014 Nov 27;371(22):2109-13. doi: 10.1056/NEJMra1407298.
American Psychiatric Association, DSM-5 Task Force. (2013). Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). American Psychiatric Publishing, Inc.. https://doi.org/10.1176/appi.books.9780890425596
Kaye AD, Staser AN, Mccollins TS, Zheng J, Berry FA, Burroughs CR et al. Delirium Tremens: A Review of Clinical Studies. Cureus. 2024 Apr 4;16(4):e57601. doi: 10.7759/cureus.57601.
European Delirium Association; American Delirium Society. The DSM-5 criteria, level of arousal and delirium diagnosis: inclusiveness is safer. BMC Med. 2014 Oct 8;12:141. doi: 10.1186/s12916-014-0141-2.
Erwin WE, Williams DB, Speir WA. Delirium tremens. South Med J. 1998 May;91(5):425-32. doi: 10.1097/00007611-199805000-00003.
Moss M, Burnham EL. Alcohol abuse in the critically ill patient. Lancet. 2006 Dec 23;368(9554):2231-42. doi: 10.1016/S0140-6736(06)69490-7.
Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Acid-base and electrolyte abnormalities in alcoholic patients. Miner Electrolyte Metab. 1994;20(5):274-81. https://pubmed.ncbi.nlm.nih.gov/7700215/
Monte R, Rabuñal R, Casariego E, López-Agreda H, Mateos A, Pértega S. Analysis of the factors determining survival of alcoholic withdrawal syndrome patients in a general hospital. Alcohol Alcohol. 2010 Mar-Apr;45(2):151-8. doi: 10.1093/alcalc/agp087.
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989 Nov;84(11):1353-7. doi: 10.1111/j.1360-0443.1989.tb00737.x.
Pullen RL Jr. Alcohol withdrawal syndrome. Nursing. 2023 Jul 1;53(7):20-27. doi: 10.1097/01.NURSE.0000936760.82108.69.
Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J. 2014 Sep;44(9):911-5. doi: 10.1111/imj.12522.
Hack JB, Hoffman RS. Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wisdom. JAMA. 1998 Feb 25;279(8):583-4. doi: 10.1001/jama.279.8.583.
Sarai M, Tejani AM, Chan AH, Kuo IF, Li J. Magnesium for alcohol withdrawal. Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008358. doi: 10.1002/14651858.CD008358.pub2.
Poikolainen K, Alho H. Magnesium treatment in alcoholics: a randomized clinical trial. Subst Abuse Treat Prev Policy. 2008 Jan 25;3:1. doi: 10.1186/1747-597X-3-1. Erratum in: Subst Abuse Treat Prev Policy. 2008;3:5. Dosage error in article text.
Vatsalya V, Gala KS, Mishra M, Schwandt ML, Umhau J, Cave MC et al. Lower Serum Magnesium Concentrations are associated With Specific Heavy Drinking Markers, Pro-Inflammatory Response and Early-Stage Alcohol-associated Liver Injury§. Alcohol Alcohol. 2020 Mar 19;55(2):164-170. doi: 10.1093/alcalc/agaa001.
Dingwall KM, Delima JF, Gent D, Batey RG. Hypomagnesaemia and its potential impact on thiamine utilisation in patients with alcohol misuse at the Alice Springs Hospital. Drug Alcohol Rev. 2015 May;34(3):323-8. doi: 10.1111/dar.12237.
Maguire D, Burns A, Talwar D, Catchpole A, Stefanowicz F, Ross DP et al. Randomised trial of intravenous thiamine and/or magnesium sulphate administration on erythrocyte transketolase activity, lactate concentrations and alcohol withdrawal scores. Sci Rep. 2022 Apr 28;12(1):6941. doi: 10.1038/s41598-022-10970-x.
McIntosh C, Chick J. Alcohol and the nervous system. J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3(Suppl 3):iii16-21. doi: 10.1136/jnnp.2004.045708.
Caputo F, Agabio R, Vignoli T, Patussi V, Fanucchi T, Cimarosti P, et al. Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol. Intern Emerg Med. 2019 Jan;14(1):143-160. doi: 10.1007/s11739-018-1933-8.
Talbot PA. Timing of efficacy of thiamine in Wernicke's disease in alcoholics at risk. J Correct Health Care. 2011 Jan;17(1):46-50. doi: 10.1177/1078345810385913.
Jesse S, Bråthen G, Ferrara M, Keindl M, Ben-Menachem E, Tanasescu R, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017 Jan;135(1):4-16. doi: 10.1111/ane.12671.
Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD008537. doi: 10.1002/14651858.CD008537.pub2.
Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997 Jul 9;278(2):144-51. doi: 10.1001/jama.278.2.144.
Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, et al. Working Group on the Management of Alcohol Withdrawal Delirium, Practice Guidelines Committee, American Society of Addiction Medicine. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004 Jul 12;164(13):1405-12. doi: 10.1001/archinte.164.13.1405. Erratum in: Arch Intern Med. 2004 Oct 11;164(18):2068. Dosage error in article text.
Muzyk AJ, Leung JG, Nelson S, Embury ER, Jones SR. The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. Am J Addict. 2013 Mar-Apr;22(2):113-8. doi: 10.1111/j.1521-0391.2013.00307.x.
Wolf C, Curry A, Nacht J, Simpson SA. Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2020 Mar 19;12:53-65. doi: 10.2147/OAEM.S235288.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020 May/Jun;14(3S Suppl 1):1-72. doi: 10.1097/ADM.0000000000000668. Erratum in: J Addict Med. 2020 Sep/Oct;14(5):e280. doi: 10.1097/ADM.0000000000000731.
Cassidy EM, O'Sullivan I, Bradshaw P, Islam T, Onovo C. Symptom-triggered benzodiazepine therapy for alcohol withdrawal syndrome in the emergency department: a comparison with the standard fixed dose benzodiazepine regimen. Emerg Med J. 2012 Oct;29(10):802-4. doi: 10.1136/emermed-2011-200509.
Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med. 2002 May 27;162(10):1117-21. doi: 10.1001/archinte.162.10.1117.
Holleck JL, Merchant N, Gunderson CG. Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. J Gen Intern Med. 2019 Jun;34(6):1018-1024. doi: 10.1007/s11606-019-04899-7.
Weaver MF, Hoffman HJ, Johnson RE, Mauck K. Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity. J Addict Dis. 2006;25(2):17-24. doi: 10.1300/j069v25n02_03.
Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants -- an update. J Clin Pharm Ther. 1998 Oct;23(5):331-6. doi: 10.1046/j.1365-2710.1998.00175.x.
Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005064. doi: 10.1002/14651858.CD005064.pub3.
Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006266. doi: 10.1002/14651858.CD006266.pub2.
Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res. 1999 Oct;23(10):1596-604. https://doi.org/10.1111/j.1530-0277.1999.tb04049.x
Caputo F, Skala K, Mirijello A, Ferrulli A, Walter H, Lesch O, et al. Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial. CNS Drugs. 2014 Aug;28(8):743-52. doi: 10.1007/s40263-014-0183-1.
Gulati P, Chavan BS, Sidana A. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Indian J Psychiatry. 2019 Jan-Feb;61(1):60-64. doi: 10.4103/psychiatry.IndianJPsychiatry_40_17.
Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006 Mar;119(3):276.e13-8. doi: 10.1016/j.amjmed.2005.08.042.
Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 2019 Nov 6;2019(11):CD008502. doi: 10.1002/14651858.CD008502.pub6.
Sychla H, Gründer G, Lammertz SE. Comparison of Clomethiazole and Diazepam in the Treatment of Alcohol Withdrawal Syndrome in Clinical Practice. Eur Addict Res. 2017;23(4):211-218. doi: 10.1159/000480380.
Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010 Feb;105(2):288-99. doi: 10.1111/j.1360-0443.2009.02792.x.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Piotr Ćwikła, Ewelina Machała-Ćwikła, Kacper Szeląg, Piotr Zdziebło, Dominika Machała, Urszula Łapińska, Antoni Kujawski, Kamila Machała
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 181
Number of citations: 0